BIOCOMPATIBILITY IN THIS SECTION. Cytotoxicity Testing

Transcription

1 BIOCOMPATIBILITY Medical devices and their component materials may leach compounds or have surface characteristics that may produce undesirable effects when used clinically. The selection and evaluation of materials and devices intended for use in humans requires a structured program of assessment to establish biocompatibility and safety. Current regulations, whether in accordance with the U.S. Food and Drug Administration (FDA), the International Organization for Standardization (ISO), or the Japanese Ministry of Health, Labor and Welfare (MHLW), require that manufacturers conduct adequate safety testing of their finished devices through pre-clinical and clinical phases as part of the regulatory clearance process. The FDA, ISO, and MHLW guidelines provide a general testing framework to aid manufacturers in the assessment of device biocompatibility. The number and type of specific safety tests required to assess product safety and compliance are dependent on the individual characteristics of the device, its component materials, and its intended clinical use. Within the general safety testing framework, it remains the responsibility of the device manufacturer to select and justify the specific tests most appropriate for the establishment of product safety and compliance with FDA, ISO, and MHLW requirements. It is recommended that testing be performed to comply with GLP regulations. WuXi AppTec, with many years of experience in biocompatibility testing, provides exceptional expertise to assist medical device manufacturers in designing thorough, well constructed testing programs to satisfy regulatory requirements. NOTE: All samples for biocompatibility testing should be sent to WuXi AppTec s St. Paul facility. As applicable, samples should be submitted after exposure to the Sponsor s sterilization process. Cytotoxicity Testing IN THIS SECTION Genotoxicology / Mutagenicity Testing Hemocompatibility Testing Implantation Testing Irritation / Intracutaneous Testing Pyrogenicity Testing Sensitization Testing Subacute / Subchronic Toxicity Testing Systemic Toxicity Testing Carcinogenicity Testing Plastics Testing Biocompatibility tests for classifications of plastics (USP) MHLW Testing Testing services designed specifically to meet the requirements of the Japanese Ministry of Health, Labor and Welfare (MHLW) REFERENCE INFORMATION Guide to Assessing Biocompatibility Testing Needs [Chart] Device Categories Biocompatibility Testing Matrix [Based on US FDA Guidance issued June 16, 2016] Quick Guide to Sample Requirements for Biocompatibility Tests [Chart] BIOCOMPATIBILITY WuXi AppTec A-1

2 CYTOTOXICITY TESTING Cytotoxicity tests involve the exposure to cell culture of substances extracted from test material. Cell cultures are extremely sensitive to minute quantities of leachable chemicals and readily display characteristic signs of toxicity in the presence of potentially harmful leachables. The tests are frequently used during product planning stages to qualify the use of a material and as a periodic check for routinely used materials to ensure that no shift in quality has occurred. Cytotoxicity in vitro testing is also required in testing the biocompatibility of materials. Typical testing programs will utilize the ISO test method to meet international regulatory requirements. The USP test method is performed to meet the FDA s U.S. regulatory requirements. Screening tests can be performed to characterize materials or to evaluate new materials against established ones. AGAROSE OVERLAY 1 ml liquid (sterile) Sufficient material to produce 3 patches, 1cm x 1cm each 7 days 14 days (GLP) L-929 mouse fibroblast cells are overlayed with a permeable agar film. A solid sample or liquid saturated disc is then placed in triplicate containers on the agar surface. Cells are examined at 24 hours for signs of toxicity (GLP) ISO Agarose Overlay Using L-929 Mouse Fibroblast Cells L-929 mouse fibroblast cells are overlayed with a permeable agar film. A solid sample or liquid saturated disc is then placed in duplicate containers on the agar surface. Cells are examined at 24 hours for signs of toxicity (GLP) USP Agarose Overlay Using L-929 Mouse Fibroblast Cells MRC-5 human embryonic lung cells are overlayed with a permeable agar film. A solid sample or liquid saturated disc is then placed in triplicate containers on the agar surface. Cells are examined at 24 hours for signs of toxicity ISO Agarose Overlay Using MRC-5 Human Embryonic Lung Cells BIOCOMPATIBILITY WuXi AppTec A-3

3 CYTOTOXICITY TESTING MEM ELUTION By Thickness Liquids < 0.5mm thick >0.5mm thick (Low density material) 30 cm 2 15 cm 2 1 g 0.5 g 5 ml Tests are set up 7 days a week, with the exception of holidays. Samples should arrive at least one business day prior to testing (GLP) ISO MEM Elution Using L-929 Mouse Fibroblast Cells Solid materials are extracted in cell culture medium and the extracts are then placed in triplicate containers of L-929 mouse fibroblast cells. Cells are examined at 24, 48 and 72 hours for signs of toxicity. 7 days 18 days (GLP) (GLP) ISO MEM Elution Using L-929 Mouse Fibroblast Cells (Liquid Test Article) Liquid test articles are mixed with cell culture medium and then placed in triplicate containers of L-929 mouse fibroblast cells. Cells are examined at 24, 48 and 72 hours for signs of toxicity. 7 days 18 days (GLP) (GLP) USP MEM Elution Using L-929 Mouse Fibroblast Cells Solid materials are extracted in cell culture medium and the extracts are then placed in duplicate containers of L-929 mouse fibroblast cells. Cells are examined at 24 and 48 hours for signs of toxicity. 7 days 18 days (GLP) (GLP) ISO MEM Endpoint Dilution Using L-929 Mouse Fibroblast Cells If a material is suspected to have cytotoxic properties, performing the cytotoxicity test with dilutions can be useful. Eight 2-fold dilutions are made to determine the toxic endpoint. Performance of the test will result in an estimation of the relative "strength" of the cytotoxic substance in the material. 7 days 18 days (GLP) A-4 WuXi AppTec BIOCOMPATIBILITY

4 CYTOTOXICITY TESTING Solid materials are extracted in cell culture medium and the extracts are then placed in triplicate containers of MRC-5 human embryonic lung cells. Cells are examined at 24, 48 and 72 hours for signs of toxicity. 7 days 18 days (GLP) (GLP) ISO MEM Elution Using MRC-5 Human Embryonic Lung Cells If a material is suspected to have cytotoxic properties, performing the cytotoxicity test with dilutions can be useful. Eight 2-fold dilutions are made to determine the toxic endpoint. Performance of the test will result in an estimation of the relative "strength" of the cytotoxic substance in the material. 18 days ISO MEM Endpoint Dilution Using MRC-5 Human Embryonic Lung Cells If a material is suspected to have cytotoxic properties, performing the cytotoxicity test with dilutions can be useful. Eight 2-fold dilutions are made to determine the toxic endpoint. Performance of the test will result in an estimation of the relative "strength" of the cytotoxic substance in the material. 7 days 18 days (GLP) (GLP) ISO MEM Endpoint Dilution Using L-929 Mouse Fibroblast Cells for Liquids Solid materials are extracted in cell culture medium and the extracts are then placed in triplicate containers of L-929 mouse fibroblast cells. Cells are examined at 24, and 48 hours for signs of toxicity. 7 days 18 days (GLP) (GLP) ISO MEM Elution Using L-929 Mouse Fibroblast Cells 48 Hour Reading Solid materials are extracted in cell culture medium. Multiple dilutions of the extract are prepared and added to triplicate wells. After incubation, the MTT reagent {3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide} is added to each well. After a second incubation, the amount of formazan formed is determined. Cytotoxicity is calculated based on the formazan levels (GLP) MTT Cytotoxicity Using L-929 Mouse Fibroblast Cells By Thickness <0.5mm thick >0.5mm thick (Low density) 36 cm 2 18 cm g 0.8 g 19 days 26 days (GLP) BIOCOMPATIBILITY WuXi AppTec A-5

5 CYTOTOXICITY TESTING (GLP) A sample is placed in direct contact with MRC-5 human embryonic lung cells. Cells are examined at 24 hours for signs of toxicity. Direct Contact Cytotoxicity Using MRC-5 Human Embryonic Lung Cells 3 samples of 1 cm 2 solid (sterile) 7 days 18 days (GLP) (GLP) A sample is placed in direct contact with L-929 mouse fibroblast cells. Cells are examined at 24 hours for signs of toxicity. ISO Direct Contact Cytotoxicity Using L-929 Mouse Fibroblast Cells 3 samples of 1 cm 2 solid (sterile) 7 days 18 days (GLP) (GLP) Neutral Red Uptake (NRU) Cytotoxicity This assay is used to measure the viability of cells after exposure to a test material extract by measurement of their ability to incorporate and bind neutral red (NR), a supravital dye. By Thickness 0.5mm thick >0.5mm thick 2 g 60 cm 2 30 cm 2 Low density: 1 g 24 days 31 days (GLP) (GLP) Colony Formation Cytotoxicity Using V79 Cells This assay is used to measure the viability of cells after exposure to a test material extract by measurement of their ability to incorporate and bind neutral red (NR), a supravital dye. By Thickness Liquids 0.5mm thick >0.5mm thick 2 g 5 ml 30 cm 2 15 cm 2 Low density: 1 g 24 days 31 days (GLP) A-6 WuXi AppTec BIOCOMPATIBILITY

6 GENOTOXICOLOGY TESTING Genotoxicology (mutagenicity) tests evaluate the ability of a material to cause mutation or gross chromosomal damage. Any materials intended for implantation or long-term exposure should be evaluated for mutagenic properties. Unpolymerized materials, additives, trace monomers or oligomers and biodegradative products can all be potential mutagens. Extracts are prepared using solutions that will extract both hydrophilic (polar) and lipophilic (non-polar) compounds possibly present in device materials. Generally, medical devices require the use of one dose (the undiluted extract) for regulatory submission, unless significant toxicity is anticipated. In addition to the genotoxicology tests listed on the following pages, other tests are available. For more information, contact your WuXi AppTec Account Manager. These tests are performed according to ISO using OECD test method 471. Tester strains of bacteria are exposed to extracts of the test material in the presence and absence of an exogenous metabolic activation system. One dose level of the test article per extract and both positive and negative controls are used. EXTRACT OPTIONS Polar Extract (Normal Saline) Non-polar Extracts (DMSO or PEG) (Per Extract) By Thickness Liquids 0.5mm thick >0.5mm thick 30 cm 2 15 cm 2 1 g Low density: 0.5 g 5 ml Salmonella Strains (GLP) Salmonella Strains Salmonella Strains + 1 E. coli Strain (GLP) Salmonella Strains + 1 E. coli Strain Salmonella Strains + 1 E. coli Strain (GLP) Salmonella Strains + 1 E. coli Strain ISO Bacterial Mutagenicity Test (Ames Assay) Two Extracts 21 days 28 days (GLP) Salmonella Strains (GLP) Salmonella Strains Salmonella Strains + 1 E. coli Strain (GLP) Salmonella Strains + 1 E. coli Strain Salmonella Strains + 1 E. coli Strain (GLP) Salmonella Strains + 1 E. coli Strain ISO Bacterial Mutagenicity Test (Ames Assay) One Extract BIOCOMPATIBILITY WuXi AppTec A-7

7 GENOTOXICOLOGY TESTING (GLP) ISO Ames Assay With Exhaustive Extraction This assay is used to evaluate the mutagenic potential of the test article (or its metabolites) by measuring its ability to induce back mutations at selected loci of four strains of Salmonella typhimurium and one strain of Escherichia coli in the presence and absence of microsomal enzymes. The test article is extracted using an exhaustive extraction, and the residue tested at five dose levels along with appropriate vehicle and positive controls. The test article dilutions are analyzed using tester strains TA98, TA100, TA1535, TA97a, and WP2- uvra with and without microsomal enzymes. The test article doses, negative vehicle, and positive controls will be plated in triplicate. Following incubation of approximately hours at 37 ± 2 C, revertant colonies per plate will be enumerated. Pretest: 2 g Method 1: TBD* OR Method 2: By Thickness Liquids 0.5mm thick >0.5mm thick 1.4 g Inquire 42 cm 2 21 cm 2 Low density: 0.7 g 33 days 40 days (GLP) * During the pretest, the test article is extracted with methanol and acetone. The extracts are then rotary evaporated to a residue. The extract solvent that produces a greater residue (by weight) is used for the extraction for the main study (Method 1). Sample requirements are based on amount of residue obtained. If neither solvent produces a sufficient evaporation residue, then Method 2 extraction shall be used extract (GLP) extract extracts (GLP) extracts ISO In-Vitro Chromosome Aberration Assay in Chinese Hamster Ovary (CHO) Cells Mammalian cells are exposed to the test material or extract in the presence and absence of metabolic activation and blocked in metaphase using a spindle poison. Visualization of chromosomes is performed microscopically after hypotonic swelling, fixation and staining. The assay utilizing two extracts satisfies the ISO requirement for assessing in-vitro chromosomal aberrations. (Per Extract) By Thickness Liquids 0.5mm thick >0.5mm thick 1.4 g Inquire 42 cm 2 21 cm 2 Low density: 0.7 g 55 days 62 days (GLP) extracts (GLP) extracts ISO In-Vitro Mouse Lymphoma Assay With Extended Treatment Mouse lymphoma cells are used to determine whether a test material has the capacity to induce either point mutations or clastogenic (chromosomal breakage) events in a cultured mammalian cell line. The cell line is exposed to the test article extract for both a 4-hour period and an extended treatment for an approximate 24-hour period. Mutants can be selected and mutant frequencies derived by including a thymidine analogue (trifluorothymidine, TFT) in the culture medium of cells after exposure to test material. The assay utilizing two extracts satisfies the ISO requirement for assessing in-vitro DNA genotoxic effects. By Thickness Liquids 0.5mm thick >0.5mm thick 2 x 2 g Inquire 2 x 60 cm² 2 x 30 cm² Low density: 2 x 1 g 32 days 39 days (GLP) A-8 WuXi AppTec BIOCOMPATIBILITY

8 GENOTOXICOLOGY TESTING IN-VIVO This test is used for the detection of damage induced to the chromosomes or mitotic apparatus of erythroblasts by analysis of erythrocytes from bone marrow of treated mice. In this assay, male and female mice are injected with one dose level of the test article extract or positive or negative control. Cells are collected for analysis at 24 and 48 hours after dosing. (Per Extract) By Thickness Liquids 0.5mm thick >0.5mm thick 4 g Inquire 120 cm 2 60 cm 2 Low density: 2 g extract (GLP) extract extracts (GLP) extracts ISO In-Vivo Mouse Micronucleus Assay 48 days 55 days (GLP) BIOCOMPATIBILITY WuXi AppTec A-9

9 HEMOCOMPATIBILITY TESTING HEMOLYSIS TESTING An important measure of hemocompatibility is the hemolysis test, which measures the ability of a material or material extract to cause red blood cells to rupture. Hemolysis testing should be performed on all materials directly contacting the bloodstream, or any materials used to form a conduit for fluids entering the circulatory system (GLP) This test, intended for materials that directly contact the bloodstream or compromised tissues, is performed in triplicate and uses rabbit blood in direct contact with the test material. The degree of hemolysis is measured spectrophotometrically. ASTM Hemolysis Assay Direct Contact Method By Thickness 0.5mm thick >0.5mm thick 3 x 42 cm 2 3 x 21 cm 2 3 x 1.4 g 7 days 21 days (GLP) (GLP) ASTM Hemolysis Assay Extract Method This test, intended for materials through which fluids pass before entry into the body, is performed in triplicate and uses saline to extract leachable substances. The material is removed and rabbit blood is added to the extract. The degree of hemolysis is measured spectrophotometrically. By Thickness 0.5mm thick >0.5mm thick 3 x 60 cm 2 3 x 30 cm 2 3 x 2 g 7 days 21 days (GLP) (GLP) This test incorporates both the direct and extraction methods of contact. See test descriptions above. ASTM Hemolysis Assay Direct Contact and Extract Method By Thickness 0.5mm thick >0.5mm thick 6 x 60 cm 2 6 x 30 cm 2 6 x 2 g ASTM (F756) Method 7 days 21 days (GLP) A-10 WuXi AppTec BIOCOMPATIBILITY

10 HEMOCOMPATIBILITY TESTING The following tests are offered for evaluating the interaction of biomaterials, polymers and medical devices with circulating blood. The assays are designed to be compliant with ISO Additional studies are available. For more information, contact your WuXi AppTec Account Manager. Note: Testing a sponsor-supplied comparison product is recommended when requesting these assays to aid in clarifying interpretation of test results. The activation of complement resulting from the use of a medical device has been associated with many adverse clinical findings. An enzyme immunoassay is used to screen for complement component(s) in human serum that has been incubated with the test article. Elevated levels of complement components C3a and SC5b-9 indicate activation of the complement system. Performing both the C3a and SC5b-9 assays is preferred. Per assay: By Thickness 0.5mm thick >0.5mm thick 0.2 g 6 cm 2 3 cm 2 Low density: 0.1 g 18 days 25 days (GLP) C3a Assay (GLP) C3a Assay SC5b-9 Assay (GLP) SC5b-9 Assay C3a and SC5b-9 (GLP) C3a and SC5b-9 Complement Activation Assay C3a Assay (GLP) C3a Assay SC5b-9 Assay (GLP) SC5b-9 Assay C3a and SC5b-9 (GLP) C3a and SC5b-9 Complement Activation Assay With Sponsor-Supplied Comparison Product The PTT assay is a general screening test for the detection of coagulation abnormalities in the intrinsic coagulation pathway. The test determines the time it takes citrated human plasma to form a clot when it is exposed first to the test material, then to calcium chloride and finally to partial thromboplastin. (Partial thromboplastin is a phospholipid suspension extracted from rabbit brain cephalin.) Test results report the partial thromboplastin time, which is the time it takes the recalcified citrated plasma to clot once the partial thromboplastin has been added. Shortening of the PTT following contact with a material under standardized conditions indicates activation of the contact phase of blood coagulation. 3 x 4 cm 2 18 days 25 days (GLP) (GLP) Partial Thromboplastin Time (PTT) (GLP) Partial Thromboplastin Time (PTT) Including Sponsor-Supplied Comparison Product BIOCOMPATIBILITY WuXi AppTec A-11

11 HEMOCOMPATIBILITY TESTING (GLP) Platelet and Leukocyte Counts Platelet and leukocyte counts are evaluated before and after exposure to the test material in human blood. Counts are evaluated for changes that may indicate activation, adhesion, aggregation, or lysis. 3 x 12 cm 2 18 days 25 days (GLP) (GLP) Platelet and Leukocyte Counts Including Sponsor-Supplied Comparison Product IN-VIVO Dog 4 hr contact (GLP) Dog 4 hr contact Dog 72 hr contact (GLP) Dog 72 hr contact Dog 4 hr contact (GLP) Dog 4 hr contact Dog 72 hr contact (GLP) Dog 72 hr contact Dog 4 hr contact (GLP) Dog 4 hr contact Dog 72 hr contact (GLP) Dog 72 hr contact Pig 4 hr contact (GLP) Pig 4 hr contact Pig 72 hr contact (GLP) Pig 72 hr contact Sheep 4 hr contact (GLP) Sheep 4 hr contact Sheep 72 hr contact (GLP) Sheep 72 hr contact Test article (e.g., tubing or catheter) is implanted in the jugular veins of the animals. Usually the test article is implanted in the jugular vein on one side and a sponsor-supplied comparative control article on the contralateral side. The test article and implant sites are removed and examined for the presence of thrombi, and the vein is examined for patency (occlusion). These observations are augmented with photographs. NOTE: Contact lab for determination of correct animal model, which will depend on article diameter. Following are general guidelines: Diameter of approx. 3 mm or less = Dog Diameter of approx. 3-6 mm = Pig Diameter of over 6 mm = Sheep 2 animal: 2 test articles + 2 comparisons 3 animal: 3 test articles + 3 comparisons 4 animal: 4 test articles + 4 comparisons Length: 8-15 cm 21 days 28 days (GLP) Thromboresistance Evaluation A-12 WuXi AppTec BIOCOMPATIBILITY

12 IMPLANTATION TESTING Implantation tests assess the local effects of material or finished product in contact with living tissue. Using a needle or surgical procedure, a sample is implanted into the tissue site appropriate for the intended use of the device. The material is implanted intramuscularly into rabbits to assess the reaction of the surrounding tissue. The implants remain in the muscle for the sponsor-designated time period. If the animals exposed to the test article do not show significant signs of irritation above that observed in the concurrent test control, the test article passes the test. Scoring of the sample and control reactions will be by gross observation. For the ISO tests, after the in-life phase, tissue samples are collected and evaluated histopathologically. The final analysis of the local effect of the test article will be based on the clinical, gross and histopathologic data. Depending on the nature of the device microstructure, the specimens may be fixed to stabilize the tissue device interface and then oriented and cut-in for histology processing. Microscopic evaluation will include such things as: cell type, cell distribution, fibroplasia, and calcification. Control implants typically consist of similar dimensional pieces of USP high-density polyethylene RS (HDPE) implanted contralaterally. Sponsor supplied, clinically marketed predicate materials may be more appropriate controls used in conjunction with or in replacement of HDPE. Gross and histologic photomicrographs can be provided at the request of the sponsor. USP: Sufficient material to produce 12 implants, approx. 10mm x 3mm ISO (3 rabbits): Sufficient material to produce 15 implants, approx. 10mm x 3mm ISO (4 rabbits): Sufficient material to produce 20 implants, approx. 10mm x 3mm [For ISO, sample preparation complies with ISO ] Implant USP Implant ISO 1 wk 35 days 1 wk 49 days 2 wk 42 days 2 wk 56 days 4 wk 56 days 4 wk 70 days 8 wk 84 days 6 wk 84 days 13 wk 119 days 8 wk 98 days 9 wk 105 days 13 wk 133 days 17 wk 161 days 26 wk 225 days 39 wk 323 days 52 wk 421 days NOTE: If plastic embedding is required for the histopathology studies, turnaround times will be longer wk implant (GLP) wk implant wk implant (GLP) wk implant wk implant (GLP) wk implant wk implant (GLP) wk implant wk implant (GLP) wk implant USP Intramuscular Implantation Test (2 Rabbits) wk implant (GLP) wk implant wk implant (GLP) wk implant wk implant (GLP) wk implant wk implant (GLP) wk implant wk implant (GLP) wk implant wk implant (GLP) wk implant wk implant (GLP) wk implant wk implant (GLP) wk implant wk implant (GLP) wk implant ISO Intramuscular Implantation Test With Histopathology (3 Rabbits) wk implant (GLP) wk implant wk implant (GLP) wk implant ISO Intramuscular Implantation Test With Histopathology (4 Rabbits) BIOCOMPATIBILITY WuXi AppTec A-13

13 IMPLANTATION TESTING wk implant (GLP) wk implant wk implant (GLP) wk implant ISO Intramuscular Implantation Test With Histopathology (5 Rabbits) wk implant (GLP) wk implant wk implant (GLP) wk implant wk implant (GLP) wk implant wk implant (GLP) wk implant wk implant (GLP) wk implant ISO Intramuscular Implantation Test With Histopathology, Clinical Chemistry and Hematology (5 Rabbits) The purpose of this study is to evaluate the potential for local effects of a test article in direct contact with skeletal muscle for an extended duration. For the safety evaluation of biomaterials, the test article, or portions thereof, will be implanted in the paravertebral muscles of live rabbits. Blood will be drawn for clinical chemistry and hematology at defined intervals (if applicable). At minimum, blood will be collected pre-implant and at termination (if applicable). After a predetermined exposure period, the animals will be sacrificed and the implantation sites will be examined, harvested and fixed for histopathology. The final analysis of the local effect of the test article will be based on the clinical, gross and histopathologic data. Depending on the nature of the device microstructure, the specimens may be fixed to stabilize the tissue device interface and then oriented and cut-in for histology processing. Microscopic evaluation will include such things as: cell type, cell distribution, fibroplasia, and calcification. Control implants typically consist of similar dimensional pieces of USP high-density polyethylene RS (HDPE) implanted contralaterally. Sponsor supplied, clinically marketed predicate materials may be more appropriate controls used in conjunction with or in replacement of HDPE. Gross and histologic photomicrographs can be provided at the request of the sponsor. Sufficient material to produce 25 implants, approx. 10mm x 3mm [Sample preparation complies with ISO ] Implant Total TAT 2 wk 63 days 4 wk 77 days 13 wk 140 days 26 wk 232 days 52 wk 428 days 78 wk 610 days NOTE: If plastic embedding is required for the histopathology studies, turnaround times will be longer. A-14 WuXi AppTec BIOCOMPATIBILITY

14 IMPLANTATION TESTING A portion of the material or device is implanted subcutaneously into rats to assess the reaction of the surrounding tissue. Implants remain for the sponsor-designated time period. The sample and control tissue sites will be evaluated grossly and histopathologically. If the animals exposed to the test article do not show significant signs of irritation above that observed in the concurrent test control sites, the test article is considered equivalent to the comparator. Photomicrographs (gross and histologic) can be provided at the request of the sponsor. Sufficient material to produce 12 implants, approx. 10mm x 3mm Implant Total TAT 1 wk 49 days 2 wk 56 days 4 wk 70 days 8 wk 98 days 13 wk 133 days wk implant (GLP) wk implant wk implant (GLP) wk implant wk implant (GLP) wk implant wk implant (GLP) wk implant wk implant (GLP) wk implant USP Subcutaneous Implantation Test (5 Rats) A portion of the material or device is implanted subcutaneously into rabbits to assess the reaction of the surrounding tissue. Implants remain for the sponsor-designated time period. The sample and control tissue sites will be evaluated grossly and histopathologically. If the animals exposed to the test article do not show significant signs of irritation above that observed in the concurrent test control sites, the test article is considered equivalent to the comparator. Photomicrographs (gross and histologic) can be provided at the request of the sponsor. 3 Rabbit: Sufficient material to produce 15 implants, approx. 10mm x 3mm 4 Rabbit: Sufficient material to produce 20 implants, approx. 10mm x 3mm [Sample preparation complies with ISO ] Implant Total TAT 1 wk 49 days 2 wk 56 days 4 wk 70 days 6 wk 84 days 8 wk 98 days 9 wk 105 days 13 wk 133 days 26 wk 225 days 39 wk 323 days 52 wk 421 days NOTE: If plastic embedding is required for the histopathology studies, turnaround times will be longer wk implant (GLP) wk implant wk implant (GLP) wk implant wk implant (GLP) wk implant wk implant (GLP) wk implant wk implant (GLP) wk implant wk implant (GLP) wk implant wk implant (GLP) wk implant wk implant (GLP) wk implant ISO Subcutaneous Implantation Test With Histopathology (3 Rabbits) wk implant (GLP) wk implant wk implant (GLP) wk implant ISO Subcutaneous Implantation Test With Histopathology (4 Rabbits) BIOCOMPATIBILITY WuXi AppTec A-15

15 IMPLANTATION TESTING wk implant (GLP) wk implant wk implant (GLP) wk implant wk implant (GLP) wk implant wk implant (GLP) wk implant ISO Subcutaneous Implantation Test With Histopathology, Clinical Chemistry and Hematology (5 Rabbits) The purpose of this study is to evaluate the potential for local effects of a test article, intended for human use, when implanted into the subcutaneous tissue of the rabbit for an extended duration. For the safety evaluation of a test article, the entire device or appropriate samples and an appropriate reference control will be implanted in the subcutaneous tissues of live rabbits. Blood will be drawn for clinical chemistry and hematology at defined intervals. At a minimum, blood will be collected pre-implant and on study termination. After a predetermined exposure period, the animals will be sacrificed and the implantation sites will be examined, harvested and fixed for histopathology. The final analysis of the local effect of the test article will be based on the clinical, gross and histopathologic data. Depending on the nature of the device microstructure, the specimens may be fixed to stabilize the tissue device interface and then oriented and cut-in for histology processing. Microscopic evaluation will include such things as: cell type, cell distribution, fibroplasia, and calcification. Control implants typically consist of similar dimensional pieces of USP high-density polyethylene RS (HDPE) implanted contralaterally. Sponsor supplied, clinically marketed predicate materials may be more appropriate controls used in conjunction with or in replacement of HDPE. Gross and histologic photomicrographs can also be provided at the request of the sponsor. Sufficient material to produce 25 implants, approx. 10mm x 3mm [Sample preparation complies with ISO ] Implant Total TAT 2 wk 63 days 4 wk 77 days 13 wk 140 days 26 wk 232 days NOTE: If plastic embedding is required for the histopathology studies, turnaround times will be longer. Custom Implant Studies Intramuscular or Subcutaneous Implant Screen Test WuXi AppTec s professional staff can assist in the design and implementation of customized studies to investigate medical device biocompatibility issues. These studies help determine whether specific device surface characteristics, polymeric composition, and physical geometry may effect local tissue responses such as inflammation, tissue ingrowth, vascularization or fibroplasia. Gross and histologic photomicrographs can also be provided at the request of the sponsor. For other custom implant studies, such as bone, intracranial and intraperitoneal implants, contact your Account Manager. A-16 WuXi AppTec BIOCOMPATIBILITY

16 IRRITATION TESTING Irritation (reactivity) tests assess the localized reaction of tissues to device materials or extracts. The selection of a test method is based on intended patient contact type. For breached tissue and blood contact, the intracutaneous test is usually selected. The dermal irritation test usually involves direct contact with the test material. The mucosal irritation test can involve either direct contact or use of extracts. Extracts are prepared using solvents that will extract either hydrophilic (polar) or lipophilic (non-polar) compounds that may be present in the device materials. Test material solution or an extract of a device is injected intracutaneously into rabbits to assess the possible irritancy of test article compounds. The animals are observed for dermal reactions over a 72-hour period. If the animals do not show significant signs of irritation above those animals observed in the concurrent test control groups, the test article passes the test. Gross photography can be requested. EXTRACT OPTIONS Normal Saline Sesame Oil 5% Ethanol in Saline Polyethylene Glycol For ISO, normal saline and/or sesame oil extracts are recommended. (Per Extract) By Thickness 0.5mm thick >0.5mm thick 36 cm 2 18 cm 2 Sample preparation complies with ISO days 29 days (GLP) (Low density) Liquids 3 x 2 g 0.6 g Inquire extracts (GLP) extracts extract (GLP) extract extracts (GLP) extracts No extraction (GLP) No extraction USP Intracutaneous Irritation Test (2 rabbits) extracts (GLP) extracts extract (GLP) extract extracts (GLP) extracts No extraction (GLP) No extraction ISO Intracutaneous Irritation Test (3 rabbits) BIOCOMPATIBILITY WuXi AppTec A-17

17 IRRITATION TESTING extracts (GLP) extracts extract (GLP) extract No extraction (GLP) No extraction ISO Mucosal (Vaginal) Irritation Test (6 rabbits per extract) Materials that come in direct or indirect contact with mucosal tissue can be assessed as to irritation potential by repeated injection of a test article solution or extract into rabbit vaginas. Acute irritation is evaluated by gross observation and histopathology of the vaginal mucosa and submucosa. Usually an application is performed on each of five days unless longer treatment is indicated due to the use of the device. Final evaluation is based on histopathological evaluation. EXTRACT OPTIONS (Per Extract) Normal Saline Sesame Oil By Thickness 0.5mm thick >0.5mm thick 5 x 60 cm 2 5 x 30 cm 2 (Low density) Liquids 5 x 2 g 5 x 1 g Inquire Sample preparation complies with ISO days 54 days (GLP) (GLP) extracts (GLP) extracts extract (GLP) extract ISO Primary Skin Irritation Test (3 rabbits) This test is performed to assess the potential for topical irritation from acute exposure or use of the device material. The material is applied to intact skin of three (3) rabbits and left in contact for 4 or 24 hours. (Extracts are used for irregularly shaped materials.) An estimate of irritation, erythema (redness) and edema (swelling) is made during the next 72 hours. Histopathologic evaluation and photomicrographs (gross and histologic) can also be provided at the request of the sponsor. NOTE: Sponsor specifies contact duration on test request form. Sufficient material to produce 7 patches, approx. 2.5cm x 2.5cm each 5 ml of liquid 23 days 30 days (GLP) A-18 WuXi AppTec BIOCOMPATIBILITY

18 IRRITATION TESTING This assay is in compliance with the recommendations in ISO and provides a quantitative method to screen materials for irritation potential, utilizing a threedimensional human epidermal model to evaluate the potential to cause skin irritation. After application of the extract to the tissue construct and incubation, the cell viability is measured through an MTT endpoint. It is recommended that test samples be prescreened for suitability prior to initiation of the main assay Extract Screening (GLP) Extract Screening extracts (GLP) extracts By Thickness 0.5mm thick >0.5mm thick 2 x 30 cm 2 2 x 15 cm 2 (Low density) 2 x 1 g 2 x 0.5 g ISO In-Vitro Skin Irritation Test Extract Screening 21 days 28 days (GLP) 2 extracts 35 days 42 days (GLP) NOTE: For information on additional irritation tests, contact your WuXi AppTec Account Manager. BIOCOMPATIBILITY WuXi AppTec A-19

19 PYROGENICITY TESTING (IN VIVO) Pyrogenicity tests determine the potential of materials, extracts, and/or a finished device to induce a pyrogenic (fever) response from sources other than endotoxin. NOTE: Bacterial endotoxin (the most commonly encountered type of pyrogen) can be readily detected and quantified using in-vitro Bacterial Endotoxin/Limulus Amebocyte Lysate (LAL) tests. For information on LAL tests, see this catalog s Microbiology section (GLP) USP Rabbit Pyrogen Test (3 rabbits) The test articles are prepared in a sterile solution, which is injected intravenously into three (3) rabbits to assess pyrogenicity. The animals are observed over a 3-hour period for an increase in body temperature. If the animals exposed to the solution do not show significant increase in body temperature, the test article passes the test. If any single animal of the three has a temperature increase above the acceptable range, the test can be continued with 5 additional animals at client s request. Transfusion / Infusion Assemblies and Similar Devices: 10 device assemblies to represent the lot under test. Blood and Tissue Contact Devices: 10 devices to represent the lot under test. 25 days 32 days (GLP) (GLP) No extraction (GLP) No extraction To assess pyrogenicity, injections are made intravenously into rabbits. For extraction testing, an extract of the test article is prepared in a sterile saline solution. The animals are observed over a 3-hour period for an increase in body temperature. If the animals do not show significant increase in body temperature, the test article passes the test. ISO Rabbit Pyrogen Materials Mediated (3 rabbits) (GLP) EP Rabbit Pyrogen Test (5 rabbits) EXTRACT OPTION Normal Saline ISO By Thickness 0.5mm thick >0.5mm thick 900 cm cm 2 EP By Thickness 0.5mm thick >0.5mm thick 1350 cm cm 2 (Low density) Liquid 30 g 15 g Inquire (Low density) Liquid 45 g 22.5 g Inquire 19 days 26 days (GLP) A-20 WuXi AppTec BIOCOMPATIBILITY

20 SENSITIZATION TESTING Sensitization tests estimate the potential for contact sensitization of devices through the testing of appropriate materials or extracts. For submissions to the FDA or MHLW, the ISO Guinea Pig Maximization Sensitization assay should be chosen. For submission solely within the European Union, the Murine Local Lymph Node Assay (LLNA) can be used. The LLNA, which is gaining acceptance as a standard methodology for sensitization studies, offers greater sensitivity and specificity than the guinea pig assays, and when combined with interpretation based on statistical data analysis between test and negative control groups it has become a recognized model for determination of delayed-type hypersensitivity. However, the effectiveness of the LLNA assay in detecting sensitizing metals is limited. For devices containing metals, the ISO Guinea Pig Maximization Sensitization assay should be used. In this assay, the ability of a material to potentially elicit a delayed-type hypersensitivity response is evaluated by the ability to cause mitotic proliferation of lymphocytes within the draining auricular lymph nodes. The standard assay utilizes three groups of mice test article, positive control and negative control (n=15 total). Adult female CBA strain mice are treated topically with solutions or extracts applied to the dorsum of the ears bilaterally. The response is compared to appropriate concurrent positive and negative controls. Measurement of the degree of cell proliferation is quantified by the incorporation of 3 H-thymidine into DNA of replicating lymph node lymphocytes. Interpretation is based on a statistically significant difference in the stimulation index (SI) between the test and negative control groups, with the test article s SI to be equal or greater than 3.0 for a positive response. Assay performance requires the positive control's SI be equal to or greater than extracts (GLP) extracts extract (GLP) extract No extraction (GLP) No extraction Murine Local Lymph Node Assay (LLNA) EXTRACT OPTIONS Normal Saline Dimethyl Sulfoxide/Polyethylene Glycol (Per Extract) By Thickness <0.5mm thick >0.5mm thick (Low density) Liquid 3 x 30 cm 2 3 x 15 cm 2 3 x 1 g 3 x 0.5 g Inquire 25 days 32 days (GLP) BIOCOMPATIBILITY WuXi AppTec A-21

21 SENSITIZATION TESTING extracts (GLP) extracts extract (GLP) extract No extraction (GLP) No extraction ISO Guinea Pig Maximization Sensitization Test Guinea pigs are exposed to test article solution or extract(s) twice within a 2-week period (Inductions I and II). The animals are re-exposed (challenged) 14 ± 1 days after Induction II by placing fresh solution or extract in contact with previously unexposed skin. At 24 and 48 hours after removal of the challenge wrap, the animals are observed for signs of a delayed allergic response when compared to a control group. If the test results are equivocal, a re-challenge can be conducted within 7-14 days of the initial challenge. NUMBER OF ANIMALS EXTRACT OPTIONS 11 test 6 irritant controls (if needed) 5 negative controls Normal Saline Sesame Oil (Per Extract) By Thickness <0.5mm thick >0.5mm thick (Low density) Liquid 3 x 60 cm 2 3 x 30 cm 2 3 x 2 g 3 x 1 g Inquire Sample preparation complies with ISO days 47 days (GLP) (GLP) Repeated Patch Dermal Sensitization Test [Buehler Method modified for medical devices] Guinea pigs are occlusively patched with the test article three days each week for three weeks. The contact duration will be 6 hours ± 30 minutes. A negative control will be similarly patched to six designated guinea pigs. Fourteen ± 1 days after the last induction patch, the animals are shaved on the opposite flank and patched with the respective test or control article for 6 hours ± 30 minutes. After removal of the patches, the sites will be scored for erythema and edema and assessed for incidence and severity of a sensitization reaction. NUMBER OF ANIMALS 11 test 6 controls Sufficient material to produce 116 patches, approx. 2.5 cm x 2.5 cm each 50 ml of liquid 50 days 57 days (GLP) A-22 WuXi AppTec BIOCOMPATIBILITY

22 SENSITIZATION TESTING Test samples are extracted using the exhaustive extraction method. Guinea pigs are exposed to the extract twice within a 2-week period (Inductions I and II). The animals are re-exposed (challenged) 14 ± 1 days after Induction II by placing fresh extract in contact with previously unexposed skin. At 24 and 48 hours after removal of the challenge wrap, the animals are observed for signs of a delayed allergic response when compared to a control group. If the test results are equivocal, a re-challenge can be conducted within 7-14 days of the initial challenge. Pretest: 20 g Method 1: TBD* or Method 2: 15 g (GLP) ISO Guinea Pig Maximization Sensitization Test (Method for Polymeric Devices) * During the pretest, the test article is extracted with methanol and acetone. The extracts are then rotary evaporated to a residue. The extract solvent that produces a greater residue (by weight) is used for the extraction for the main study (Method 1). Sample requirements are based on amount of residue obtained. If neither solvent produces a sufficient evaporation residue, then Method 2 extraction shall be used. 67 days 74 days (GLP) Guinea pigs are exposed to the liquid test article twice within a 2-week period (Inductions I and II). The animals are re-exposed (challenged) 14 ± 1 days after Induction II by placing test article in contact with previously unexposed skin. At 24 and 48 hours after removal of the challenge wrap, the animals are observed for signs of a delayed allergic response when compared to a control group. If the test results are equivocal, a re-challenge can be conducted within 7-14 days of the initial challenge. 15 ml 40 days 47 days (GLP) (GLP) ISO Guinea Pig Maximization Sensitization Test (Method for Liquid Test Article) Guinea pigs will be shaved and occlusively patched with the sponsor-supplied test article one day each week for 3 weeks. The contact duration will be 6 hours ± 30 minutes. A negative control will be similarly patched to six (6) designated guinea pigs. Fourteen days after the last induction patch, the animals will be shaved on the opposite flank and patched with the respective test or control article for 6 hours ± 30 minutes. After removal of the patches the sites will be scored for erythema and edema and assessed for incidence and severity of a sensitization reaction. 50 ml (GLP) Buehler Dermal Sensitization Test (Method for Chemical Compounds) 50 days 57 days (GLP) BIOCOMPATIBILITY WuXi AppTec A-23

23 SUBACUTE / SUBCHRONIC TOXICITY TESTING Subacute toxicity is assessed after single or multiple exposures to extracts of device materials. The exposure period is longer than typical acute toxicity tests, but not exceeding 10% of animal lifespan. Subchronic toxicity is assessed after repeated intravenous injections of the device materials extract. These studies involve expanded evaluations and can include systemic changes, local irritation, body weight, blood values and tissue changes as part of the protocol. The length of time for the test and the parameters evaluated will depend on the end use of the device. WuXi AppTec will assist in the test program design. For special subacute/subchronic toxicity testing involving dermal, intramuscular, subcutaneous, mucosal or oral dosing programs, contact your Account Manager. All of the following include Histopathology, Clinical Chemistry and Hematology. Inquire if Histopathology is not required day / 5 dose day / 14 dose day / 5 dose Multiple extracts of a device are prepared and injected into 6 male and 6 female mice or rats over the test time period. Two similar control groups are also injected with control vehicle. The animals are observed during the test time period for signs of toxicity and are subjected to a gross observation at study termination. The test article passes if the test parameters (weight, survival, clinical observations and gross necropsy) are not significantly different from the concurrent control animal parameters. Other parameters evaluated include clinical chemistry and hematology. ISO Subacute Intraperitoneal Toxicity Study Mice (GLP) EXTRACT OPTIONS Sesame Oil (intraperitoneal injections) Normal Saline (intravenous injections) (Per Extract) day / 5 dose day / 14 dose day / 14 dose ISO Subacute Intraperitoneal Toxicity Study Rats (GLP) day / 5 dose day / 14 dose day / 5 dose ISO Subchronic Intravenous Toxicity Study Mice (GLP) By Thickness <0.5mm thick >0.5mm thick (Low density) x 30 cm 2 5 x 15 cm 2 5 x 1 g 5 x 0.5 g x 30 cm 2 14 x 15 cm 2 14 x 1 g 14 x 0.5 g x 90 cm² 5 x 45 cm² 5 x 3 g 5 x 1.5 g x 90 cm² 14 x 45 cm² 14 x 3 g 14 x 1.5 g x 30 cm 2 5 x 15 cm 2 5 x 1 g 5 x 0.5 g x 90 cm² 14 x 45 cm² 14 x 3 g 14 x 1.5 g x 48 cm 2 5 x 24 cm 2 5 x 1.6 g 5 x 0.8 g x 48 cm 2 14 x 24 cm 2 14 x 1.6 g 14 x 0.8 g x 48 cm 2 5 x 24 cm 2 5 x 1.6 g 5 x 0.8 g x 270 cm² 5 x 135 cm² 5 x 9 g 5 x 4.5 g x 270 cm² 14 x 135 cm² 14 x 9 g 14 x 4.5 g x 270 cm² 28 x 135 cm² 28 x 9 g 28 x 4.5 g Sample preparation complies with ISO day / 5 dose day / 14 dose day / 28 dose 14-Day Studies: 82 days 28- and 30-Day Studies: 98 days ISO Subchronic Intravenous Toxicity Study Rats (GLP) A-24 WuXi AppTec BIOCOMPATIBILITY

24 SYSTEMIC TOXICITY TESTING Toxicity tests estimate the potential harmful systemic effects from a single exposure to polar or nonpolar extracts of device materials. Test article solution or extract is injected into mice (5 per solution/extract, 5 per control) to assess the possible toxicity of compounds in the test article. The animals are observed over a 72-hour period. If the animals exposed to the test article do not show signs of toxicity greater than the concurrent control groups, the test article passes the test. EXTRACT OPTIONS Normal Saline Sesame Oil 5% Ethanol in Saline Polyethylene Glycol extracts (GLP) extracts extract (GLP) extract extracts (GLP) extracts No extraction (GLP) No extraction USP Acute Systemic Injection Test For ISO, normal saline and/or sesame oil extracts are recommended. (Per Extract) By Thickness Liquids 0.5mm thick >0.5mm thick 1.6 g Inquire 48 cm 2 24 cm 2 Low density: 0.8 g For ISO, sample preparation complies with ISO days 27 days (GLP) extracts (GLP) extracts extract (GLP) extract extracts (GLP) extracts No extraction (GLP) No extraction ISO Acute Systemic Injection Test BIOCOMPATIBILITY WuXi AppTec A-25

25 CARCINOGENICITY TESTING Custom These tests are often long-term studies that can extend for a period of up to two years or longer. If the device involves new chemistry that (from material characterization and exposure assessments) indicate a high enough risk, one or more of these studies may be necessary. Contact your Account Manager for information and/or assistance in designing an appropriate long-term study. A-26 WuXi AppTec BIOCOMPATIBILITY

26 PLASTICS TESTING USP Class Testing is designed to determine the biological response of animals to elastomerics, plastics and other polymeric material with direct or indirect patient contact, or by the injection of specific extracts prepared from the material under test. Six Plastic Classes are defined. (See table below.) Classification is based on responses to a series of in-vivo tests for which extracts, materials, and routes of administration are specified. These tests are directly related to the intended end-use of the plastic articles. The choice of extractants is representative of the vehicles in preparations with which the plastics are likely to be in contact. The classification facilitates communication among suppliers, users, and manufacturers of plastics by summarizing the tests to be performed for containers for injections and medical devices if a need for classification exists. NOTE: These tests are for material qualification, not for regulatory submission. BIOCOMPATIBILITY TESTS FOR CLASSIFICATIONS OF PLASTICS (USP) All of these tests include issuance of a Certificate of Compliance upon completion USP Class I Includes Acute Systemic (NS), Intracutaneous Irritation (NS) USP Class I Includes Acute Systemic (NS), Intracutaneous Irritation (NS) (GLP) USP Class II Includes Acute Systemic (NS, AS), Intracutaneous Irritation (NS & AS) USP Class II - Includes Acute Systemic (NS, AS), Intracutaneous Irritation (NS, AS) (GLP) USP Class III Includes Acute Systemic (NS, AS, PEG, SO), Intracutaneous Irritation (NS, AS) USP Class III Includes Acute Systemic (NS, AS, PEG, SO); Intracutaneous Irritation (NS, AS) (GLP) USP Class IV Includes Acute Systemic (NS, AS, SO), Intracutaneous Irritation (NS, AS, SO), 7 Day IM Implant USP Class IV Includes Acute Systemic (NS, AS, SO), Intracutaneous Irritation (NS, AS, SO), 7 Day IM Implant (GLP) USP Class V Includes Acute Systemic (NS, AS, PEG, SO); Intracutaneous Irritation (NS, AS, PEG, SO) USP Class V Includes Acute Systemic (NS, AS, PEG, SO), Intracutaneous Irritation (NS, AS, PEG, SO) (GLP) USP Class VI Includes Acute Systemic (NS, AS, PEG, CSO), Intracutaneous Irritation (NS, AS, PEG, CSO), 7-Day IM Implant USP Class VI Includes Acute Systemic (NS, AS, PEG, SO), Intracutaneous Irritation (NS, AS, PEG, SO), 7-Day IM Implant (GLP) NS = Normal Saline AS = Alcohol Saline PEG = Polyethylene Glycol SO = Sesame Oil Contact your WuXi AppTec Account Manager for information regarding sample requirements and turnaround times. BIOCOMPATIBILITY WuXi AppTec A-27

27 MHLW TESTING Following are descriptions of WuXi AppTec testing services designed specifically to meet the most current requirements of the Japanese Ministry of Health, Labor and Welfare (MHLW), as noted in the Guidelines for Basic Biological Tests of Medical Materials and Devices. For more information on testing services to meet MHLW requirements, contact your WuXi AppTec Account Manager. CYTOTOXICITY (GLP) MHLW Cytotoxicity Test Colony Microassay By Elution The purpose of this procedure is to evaluate the cytotoxic response of a specified mammalian culture cell line when exposed to an extract of the test article. This assay utilizes the sensitivity of low cell density to evaluate the cytotoxicity of medical devices. Test articles and controls will be prepared and extracted for hours at 37 ± 1 C. Appropriate dilutions of the extracts will be prepared using E-MEM +10% FBS. After removing spent medium, 2.0 ml of the extract will be added to the plates. The cells will be incubated at 37 ± 1 C for 7-9 days before fixation, staining, and counting. 120 cm² or 2 g 24 days 31 days (GLP) REGARDING METHOD 1 IN THE FOLLOWING TESTS: During the pretest, the test article is extracted with methanol and acetone. The extracts are then rotary evaporated to a residue. The extract solvent that produces a greater residue (by weight) is used for the extraction for the main study (Method 1). Sample requirements are based on amount of residue obtained. If neither solvent produces a sufficient evaporation residue, then Method 2 extraction shall be used. GENOTOXICOLOGY (GLP) MHLW Bacterial Reverse Mutation (Ames Assay) Using 4 Salmonella Strains and 1 E. Coli Strain The purpose of this study is to evaluate the mutagenic potential of the test article (or its metabolites) by measuring its ability to induce back mutations at selected loci of four strains of Salmonella typhimurium and one strain of Escherichia coli in the presence and absence of microsomal enzymes. The test article will be extracted using an exhaustive extraction approach termed Method 1. The resulting residue will be resuspended for testing at five dose levels along with appropriate vehicle and positive controls. The test article dilutions are analyzed using tester strains TA98, TA100, TA1535, TA97a, and WP2-uvrA - with and without microsomal enzymes. The test article doses, negative vehicle, and positive controls will be plated in triplicate. Following incubation of approximately hours at 37 ± 2 C, revertant colonies per plate will be enumerated. Pretest: 10 g Method 1: TBD or Method 2: 1 g 33 days 40 days (GLP) A-28 WuXi AppTec BIOCOMPATIBILITY

28 MHLW TESTING The test article will be extracted using an exhaustive extraction. Mouse Lymphoma cells are used to determine whether a test material has the capacity to induce either point mutations or clastogenic (chromosomal breakage) events in a cultured mammalian cell line. Mutants can be selected and mutant frequencies derived by including a thymidine analogue (trifluorothymidine, TFT) in the culture medium of cells after exposure to the test material. Pretest: 10 g Method 1: TBD or Method 2: 2 g (GLP) MHLW In-Vitro Mouse Lymphoma Assay 46 days 53 days (GLP) This assay is used to evaluate the potential of the test article to induce chromosome aberrations in the Chinese Hamster Ovary (CHO) cell line with and without in vitro metabolic activation (S9). The test article will be extracted using an exhaustive extraction. CHO-K 1 cells will be incubated in the presence of the test article extract, negative, or positive control for three hours in the presence and absence of metabolic activation. After this incubation period, the cells will be washed, fresh medium added, and returned to the incubator. Two hours prior to the end of incubation, colcemid will be added to all flasks to stop cells in metaphase. The cells will be collected from the flasks by mitotic shake-off, swollen, fixed, and dropped onto slides. The slides will be stained and permanently mounted prior to microscopic observation (GLP) MHLW In-Vitro Chromosome Aberration Assay in Chinese Hamster Ovary (CHO) Cells Pretest: 10 g Method 1: TBD or Method 2: 2 g 55 days 62 days (GLP) The test article will be extracted using an exhaustive extraction. This assay is used to evaluate the potential of the test article to induce micronuclei formation in immature polychromatic erythrocytes present in the bone marrow of adult CD-1 mice. Bone marrow will be harvested after a 24- and 48-hour induction period and prepared as a single cell suspension and smeared on microscope slides and then examined microscopically for the presence of micronucleated PCEs. Pretest: 10 g Method 1: TBD or Method 2: 5 g (GLP) MHLW In-Vivo Mouse Micronucleus Assay With Exhaustive Extraction 48 days 55 days (GLP) BIOCOMPATIBILITY WuXi AppTec A-29

29 MHLW TESTING HEMOLYSIS (GLP) MHLW Hemolysis Assay The purpose of this study is to evaluate the hemolytic potential of test articles. Three healthy, mature New Zealand White rabbits of either sex, from a certified commercial vendor, will be selected as donors for this study. Three to five ml of blood will be collected from each rabbit using appropriate venipuncture, employing evacuated tubes containing 3.2% sodium citrate. The time and date of blood collection and rabbit ear tag number will be recorded directly on the vial, and the blood will be used within 6 hours of collection. Blood will be stored under refrigeration until time of use. Test articles and controls will be prepared and extracted as requested. A total of 3 replicates will be prepared for extraction. Each test article replicate will be obtained from one device. Blood will then be added to the test and control materials. These mixtures will be incubated for 1, 2, or 4 hours at 37 ±1 C. After incubation, the mixtures will be transferred to centrifuge tubes and centrifuged to remove cellular materials. A cyanmethemoglobin reagent will be added to the supernatant and these samples will be read at 540 nm on a spectrophotometer. The hemolysis will be calculated based on these results. By Thickness 0.5mm thick >0.5mm thick 3 x 120 cm 2 3 x 60 cm 2 3 x 4 g 25 days 32 days (GLP) IMPLANTATION wk implant (GLP) wk implant wk implant (GLP) wk implant wk implant (GLP) wk implant wk implant (GLP) wk implant wk implant (GLP) wk implant MHLW Intramuscular Implantation Test With Histopathology wk implant (GLP) wk implant wk implant (GLP) wk implant The purpose of this study is to evaluate the local effects of a test article in direct contact with living tissue. For the safety evaluation of a test article, representative portions of the device or the entire device are implanted in live rabbits. A maximum of 4 test samples and 4 control samples will be implanted into each of four rabbits for each time point or group. After a predetermined exposure period, the animals will be sacrificed and the implantation sites exposed. Gross necropsy observations will be made and implant sites harvested and fixed. The specimens will be fixed to stabilize the tissue device interface and then oriented transversely and cut-in for histology processing. Microscopic evaluation will include such things as: cell type, cell distribution, fibroplasia, and neovascularization. Histopathology is necessary to meet the requirements. Sufficient material to produce 20 implants, approx. 10mm x 3mm Implant Total TAT 1 wk 49 days 2 wk 56 days 4 wk 70 days 8 wk 98 days 13 wk 133 days MHLW Subcutaneous Implantation Test With Histopathology A-30 WuXi AppTec BIOCOMPATIBILITY

30 MHLW TESTING IRRITATION This test is designed to determine if test materials have the potential to cause skin irritation. Test and negative control extracts will be prepared using normal saline (NS) and sesame oil (SO). Twelve (12) rabbits will be shaved (6 rabbits per extract). The test and control extracts (0.5 ml per site) will be applied to both scratched and unscratched skin. Following application, the extracts will be covered with tapedbacked gauze (GLP) MHLW Primary Skin Irritation Test 2 Extracts After the 24-hour exposure period, the patches will be removed. Observations for skin irritation will be conducted at 60 ± 6 minutes after unwrapping, and at 24 ± 2, and 48 ± 2 hours. The test will be evaluated by an overall collection and interpretation of the data, using the dermal scores as reference marks, and based on the nature and reversibility of the skin lesions. By Thickness < 0.5mm thick >0.5mm thick 2 x 30 cm 2 2 x 15 cm 2 2 x 1 g 23 days 30 days (GLP) The purpose of this test is to determine if chemicals that may leach or be extracted from the test material are capable of causing local irritation in the dermal tissues of the rabbit. Rabbits will be injected intracutaneously (Dose = 0.2 ml x 5 sites) with test article solution or extracts and associated vehicle controls. Injection sites will be examined and scored at 24 ± 2, 48 ± 2, and 72 ± 2 hours after treatment for signs of skin reactions. In addition, the sites will be photographed following injection and at all scoring periods. If the difference between the average scores for the test article and the control are less than or equal to 1.0, the test article passes the test. (Per Extract) By Thickness < 0.5mm thick >0.5mm thick 36 cm 2 18 cm g extracts (GLP) extracts extract (GLP) extract No extraction (GLP) No extraction MHLW Intracutaneous Irritation Test 22 days 29 days (GLP) BIOCOMPATIBILITY WuXi AppTec A-31

31 MHLW TESTING PYROGENICITY (GLP) No extraction (GLP) No extraction MHLW Materials Mediated Rabbit Pyrogen Test To assess pyrogenicity, injections will be made into the marginal ear vein of each of three rabbits. For extraction testing, the test article will be extracted in 0.9% saline solution and injected. All animals will receive a 10 ml/kg dose. Rectal temperatures will be recorded for each animal prior to injection and between 1 and 3 hours post-injection (at minimum 30 minute intervals). The test article will be considered negative if none of the animals has a temperature increase 0.6 C and the cumulative temperature increase of the three animals is less than 1.4 C. If any rabbit has an individual temperature rise 0.6 C, the test may be continued, per the Sponsor s request, using five additional rabbits. If not more than two of the five animals from the continued test have a temperature increase 0.6 C the test article under examination will meet the MHLW requirements for the absence of pyrogens. By Thickness Liquid 0.5mm thick >0.5mm thick 900 cm cm 2 30 g Inquire 19 days 26 days (GLP) SENSITIZATION (GLP) MHLW Guinea Pig Maximization Sensitization Test This test, designed to evaluate the allergenic potential or sensitizing capacity of a test article, is used as a procedure for the screening of contact allergens in guinea pigs and extrapolating the results to humans, but it does not establish the actual risk of sensitization. After the material has been appropriately extracted using the exhaustive extraction method, eleven (11) test and six (6) irritant control animals will be exposed to the extract in a series of two inductions, followed approximately two weeks later by a challenge exposure at which time the animals are evaluated for a sensitization response. Pretest: 10 g Method 1: TBD* or Method 2: 20 g * During the pretest, the test article is extracted with methanol and acetone. The extracts are then rotary evaporated to a residue. The extract solvent that produces a greater residue (by weight) is used for the extraction for the main study (Method 1). Sample requirements are based on amount of residue obtained. If neither solvent produces a sufficient evaporation residue, then Method 2 (extraction) shall be used. 74 days 81 days (GLP) A-32 WuXi AppTec BIOCOMPATIBILITY

32 MHLW TESTING SUBACUTE TOXICITY This assay is used to verify that there are no substances with subacute toxicity in the extracts taken from test articles. Twenty rats (10 test / 10 control) will be administered intravenously with a normal saline extract of the test article or vehicle control daily over the course of the 28-day test period. Animals will be observed once daily for signs of toxicity. Blood samples for hematology and clinical chemistry analysis will be collected and the tissues will be collected for histopathology. By Thickness Liquid 0.5mm thick >0.5mm thick 28 x 600 cm 2 28 x 300 cm 2 28 x 20 g Inquire (GLP) MHLW Subacute Intravenous Toxicity Study With Histopathology, Clinical Chemistry and Hematology Rats 105 days SYSTEMIC TOXICITY The purpose of this test is to screen solutions or test article extracts for potential toxic effects as a result of a single-dose systemic injection in mice. For the safety evaluation of a test article, mice will be injected intraperitoneally or intravenously with either extracts or solutions of the test article or control (vehicle without test article). The animals will be observed for signs of toxicity immediately after injection and at 4 ± 0.75 hours and 24, 48, and 72 ± 2 hours post-injection. Body weights will be measured prior to injection and 24, 48, and 72 ± 2 hours post-injection. If none of the animals treated with the test article extract or solution shows a greater adverse reaction than the animals treated with the blank, the test article will pass the test. (Per Extract) By Thickness Liquid 0.5mm thick >0.5mm thick 48 cm 2 24 cm g Inquire extracts (GLP) extracts extract (GLP) extract extracts (GLP) extracts No extraction (GLP) No extraction MHLW Acute Systemic Injection Test 20 days 27 days (GLP) BIOCOMPATIBILITY WuXi AppTec A-33

33 GUIDE TO ASSESSING BIOCOMPATIBILITY TESTING NEEDS Use of International Standard ISO "Biological Evaluation of Medical Devices Part 1: Evaluation and Testing" Draft Guidance for Industry and Food and Drug Administration Staff April 23, 2013 Contains Nonbinding Recommendations Draft Not for Implementation Start Does the device contact the body directly or indirectly? No BIOCOMPATIBILITY REQUIREMENTS MET Yes Is material same in marketed device? Yes Same Yes Same Yes Same Yes manufacturing chemical body process? composition? contact? Same sterilization method? Yes No No No No No Is device material a polymer? Yes No No Acceptable justification or test data? Is material metal, metal alloy or ceramic? No Consult modified ISO matrix for suggested tests Yes Yes Does it contain any toxic substances (e.g., Pb, Ni, Cr, Zn)? Yes No Yes Consult toxicologist whether certification to a material standard is sufficient No Consult toxicologist for appropriate tests, if necessary Master File, when referenced, has acceptable biocompatibility data applicable to the device? or Submission contains acceptable biocompatibility data and/or justification or risk assessment for not conducting appropriate tests Yes Toxicologist concurrence, as necessary No BIOCOMPATIBILITY DATA REQUIRED Yes BIOCOMPATIBILITY REQUIREMENTS MET BIOCOMPATIBILITY WuXi AppTec A-35

34 DEVICE CATEGORIES DEVICE CATEGORIES BY NATURE OF CONTACT Medical devices fall into one of four categories based on the nature of patient contact: q w e r Non-Contact Devices Surface Devices External Communicating Devices Implant Devices Devices that do not directly or indirectly contact the patient are not required to undergo biocompatibility testing. Contacting Intact Skin (e.g., electrodes, external prostheses, fixation tapes, compression bandages) Contacting Mucous Membranes (e.g., contact lenses, urinary catheters, colonoscopes, endotracheal tubes) Contacting Breached or Compromised Surfaces (e.g., wound dressings, occlusive patches, healing devices) Contacting Blood Path Indirectly (e.g., solution administration sets, I.V. extension sets, blood transfusion sets) Contacting Tissue, Bone or Dentin (e.g., laparoscopes, arthroscopes, draining systems, dental cements, skin staples) Contacting Circulating Blood (e.g., intravenous and delivery catheters, temporary pacemaker electrodes, dialyzers, dialysis tubing, hemadsorbants, immuno-adsorbants) Contacting Tissue and/or Bone (e.g., orthopedic pins and plates, pacemakers, breast implants, replacement tendons, ligation clips, drug supply devices) Contacting Blood (e.g., pacemaker electrodes, heart valves, vascular grafts, ventricular assist devices, internal drug delivery devices, stents) DEVICE CATEGORIES BY DURATION OF CONTACT Devices generally are placed in one of three categories based on expected duration of contact with patient: A Limited [ 24 hours] B Prolonged [> 24 hours and 30 days] C Permanent [> 30 days] A-36 WuXi AppTec BIOCOMPATIBILITY

35 BIOCOMPATIBILITY TESTING Based on Guidance issued by the US FDA June 16, 2016 Use of International Standard ISO , "Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process" Note: The following is a framework for the development of a biocompatibility evaluation and is not a checklist for testing. For particular medical devices, different biological endpoints may require evaluation, including either additional or fewer endpoints than indicated. MEDICAL DEVICE CATEGORIES BIOLOGICAL EFFECT Nature of Body Contact Category Contact Contact Duration A Limited [ 24 hrs] B Prolonged [>24 hrs to 30 days] C Permanent [>30 days] Cytotoxicity Sensitization Irritation or Intracutaneous Reactivity Acute Systemic Toxicity Material-Mediated Pyrogenicity Subacute / Subchronic Toxicity Genotoxicity Implantation Hemocompatibility Chronic Toxicity Carcinogenicity SURFACE DEVICE EXTERNAL COMMUNICATING DEVICE IMPLANT DEVICES Intact Skin Mucosal Membrane Breached or Compromised Surface Blood Path, Indirect Tissue 1 / Bone / Dentin Circulating Blood Tissue 1 / Bone Blood A B C A B C A B C A B C A B C A 2 B C A B C A B C = ISO :2009 recommended endpoints for consideration = Additional FDA recommended endpoints for consideration = ISO All :2009 and should recommended be addressed in endpoints the biological for consideration safety evaluation through Reproductive use of / existing Developmental data, additional Toxicity endpoint-specific testing or = Additional a rationale FDA for why recommended the endpoint endpoints does not require for consideration additional assessment. Reproductive and developmental toxicity should be addressed for novel materials, materials with a known reproductive or developmental toxicity, devices with All and should be addressed in the biological safety relevant target populations (e.g., pregnant women), and/or devices where there is evaluation through use of existing data, additional endpointspecific testing Based or on a the rationale risk assessment, for why the additional endpoint tests does may not be 1 the probability for local presence of device materials in the reproductive organs. require additional necessary. assessment. For Degradation reproductive and biodegradation tests, contact your 1 Degradation information should be provided for any devices, device components, Tissue includes tissue fluids and subcutaneous spaces 2 or materials remaining in contact with tissue that are intended to degrade. For all devices used in extracorporeal circuits BIOCOMPATIBILITY WuXi AppTec A-37

36 FOR BIOCOMPATIBILITY TESTING This chart is designed as a convenient quick guide for some of our most commonly ordered tests (and does not list all available tests). Sample requirements represent total number extracts/replicates needed. For example, Partial Thromboplastin Time requires 3 replicates at 4 cm² each. The sample sizes reflect the minimum amount of sample, depending on the test being performed. For liquid samples, contact Client Services. Turnaround times for GLP testing are shown in brackets with each test listing. If not GLP testing, turnaround times would be approximately 7 days shorter. If you have questions, before submitting samples, contact Client Services at WuXi AppTec s St. Paul facility: or TESTS PERFORMED USING EXTRACTION RATIOS < 0.5mm thickness Ratio: 6cm²/1mL 0.5mm thickness Ratio: 3cm²/1mL Irregularly Shaped Ratio: 0.2g/1mL Membranes/Textiles Ratio: 0.1g/1mL CYTOTOXICITY MEM Elution Using L-929 Mouse Fibroblast Cells ISO/USP [16 days] 1 x 30cm² 1 x 15cm² 1 x 1g 1 x 0.5g MEM Endpoint Dilution Using L-929 Mouse Fibroblast Cells [16 days] 1 x 48cm² 1 x 24cm² 1 x 1.6g 1 x 0.8g MTT Cytotoxicity Using L-929 Mouse Fibroblast Cells [26 days] 1 x 36cm² 1 x 18cm² 1 x 1.2g 1 x 0.6g Neutral Red Uptake (NRU) [26 days] 2 x 42cm² 2 x 21cm² 2 x 1.4g 2 x 0.7g GENOTOXICITY Bacterial Mutagenicity (Ames) [28 days] 2 x 24cm² 2 x 12cm² 2 x 0.8g 2 x 0.4g In-Vitro Chromosome Aberration [62 days] 2 x 42cm² 2 x 21cm² 2 x 1.4g 2 x 0.7g In-Vitro Mouse Lymphoma with Extended Treatment [39 days] 2 x 60cm² 2 x 30cm² 2 x 2g 2 x 1g In-Vivo Mouse Micronucleus [48 days] 2 x 120cm² 2 x 60cm² 2 x 4g 2 x 2g IRRITATION Intracutaneous Irritation ISO/USP [29 days] 2 x 36cm² 2 x 18cm² 2 x 1.2g 2 x 0.6g Vaginal Mucosal Irritation ISO [54 days] 10 x 60cm² 10 x 30cm² 10 x 2g 10 x 1g PYROGENICITY Materials Mediated Rabbit Pyrogen ISO [26 days] 900cm² 450cm² 30g 15g SENSITIZATION Maximization Sensitization (Guinea Pig) ISO [47 days] 6 x 60cm² 6 x 30cm² 6 x 2g 6 x 1g SYSTEMIC TOXICITY Acute Systemic Toxicity ISO/USP [27 days] 2 x 48cm² 2 x 24cm² 2 x 1.6g 2 x 0.8g Subchronic Intravenous Toxicity (Mice) 14 Dose [75 days] 14 x 48cm² 14 x 24cm² 14 x 1.6g 14 x 0.8g Subacute Intraperitoneal Toxicity (Mice) 14 Dose [75 days] 14 x 30cm² 14 x 15cm² 14 x 1g 14 x 0.5g Subchronic Intravenous Toxicity (Rats) 14 Dose [75 days] 14 x 270cm² 14 x 135cm² 14 x 9g 14 x 4.5g Subacute Intraperitoneal Toxicity (Rats) 14 Dose [75 days] 14 x 90cm² 14 x 45cm² 14 x 3g 14 x 1.5g Subacute Intravenous Toxicity (Rats) 28 Dose [91 days] 28 x 270cm² 28 x 135cm² 28 x 9g 28 x 4.5g MHLW Cytotoxicity Test Colony Microassay by Elution [31 days] 120cm² 120cm² 2g 2g MHLW Hemolysis [32 days] 3 x 120cm² 3 x 60cm² 3 x 4g 3 x 2g MHLW Intracutaneous Irritation [29 days] 2 x 36cm² 2 x 18cm² 2 x 1.2g 2 x 0.6g MHLW Primary Skin Irritation [30 days] 2 x 30cm² 2 x 15cm² 2 x 1g 2 x 0.5g MHLW Materials Mediated Rabbit Pyrogen [26 days] 900cm² 450cm² 30g 15g MHLW Acute Systemic Toxicity [27 days] 2 x 48cm² 2 x 24cm² 2 x 1.6g 2 x 0.8g MHLW Subacute Intravenous Toxicity (28 Day / 28 Dose) [105 days] 28 x 600cm² 28 x 300cm² 28 x 20g 28 x 10g TESTS PERFORMED USING EXHAUSTIVE EXTRACTION METHODS Method 2 Pretest Method 1 Ratio: 0.2g/1mL Ratio: 6cm²/1mL MHLW Bacterial Reverse Mutation (Ames Assay) [40 days] 1g 30cm² 10g TO BE DETERMINED MHLW In-Vitro Mouse Lymphoma [53 days] Sample requirements based on the 18g 540cm² MHLW In-Vitro Chromosome Aberration [62 days] The pretest result can be used amount of residue obtained in the pretest 13g 390cm² MHLW In-Vivo Mouse Micronucleus [48 days] will be communicated to the client by a for any one or all of these tests. 5g 150cm² WuXi AppTec representative. MHLW Maximization Sensitization [81 days] 20g HEMOCOMPATIBILITY / BLOOD COMPATIBILITY TESTS 0.5mm thickness Ratio: 6cm²/1mL > 0.5mm thickness Ratio: 3cm²/1mL Irregularly Shaped Ratio: 0.2g/1mL Complement Activation C3a and SC5b-9 [25 days] 6cm² * 3cm² * 0.2g * Hemolysis: ASTM Direct Contact [21 days] 3 x 42cm² 3 x 21cm² 3 x 1.4g Hemolysis: ASTM Extract [21 days] 3 x 60cm² 3 x 30cm² 3 x 2g In-Vitro Hemocompatibility [25 days] 3 x 12cm² * Partial Thromboplastin Time [25 days] 3 x 4cm² * Platelet and Leukocyte Count [25 days] 3 x 12cm² * Thromboresistance (In-Vivo) [28 days] 1 test sample and 1 comparison sample per animal *Concurrent testing of sponsor-supplied comparison product is recommended. (Required for thromboresistance studies.) Sample size of the comparison product should be the same as that of the test article. TESTS PERFORMED USING THE PATCH METHOD (SKIN CONTACTING) Agarose Overlay Using L-929 Cells ISO/USP [14 days] Sufficient material l to produce 3 patches, 1cm x 1cm each Maximum of 2 materials per test Primary Skin Irritation ISO [30 days] Sufficient material to produce 7 patches, 2.5cm x 2.5cm each Maximum of 4 materials per test Repeated Patch Dermal Sensitization Test Buehler [57 days] Sufficient material to produce 116 patches, 2.5cm x 2.5cm each Maximum of 4 materials per test IMPLANTATION TESTS (Note: Turnaround times are in addition to implant duration.) Intramuscular/Subcutaneous Implantation (3 Rabbit) ISO [42 days] Sufficient material to produce 18 implants, approx. 10mm x 3mm each Intramuscular/Subcutaneous Implantation (5 Rabbit) ISO [49 days] Sufficient material to produce 28 implants, approx. 10mm x 3mm each Intramuscular Implantation USP [21 days] Sufficient material to produce 13 implants, approx. 10mm x 3mm each MHLW Intramuscular / Subcutaneous Implantation [42 days] Sufficient material to produce 18 implants, approx. 10mm x 3mm each